

Table SIII. Comparison of complete clinical clearance rates following treatment with 5-FU/SA, ingenol mebutate or imiquimod

Study drug	Vehicle arm		Active arm		Vehicle arm vs. active arm response rate difference (%)
	Patients in treatment arm (n)	Patients achieving complete response (%) <sup>c</sup>	Patients in treatment arm (n)	Patients achieving complete response (%) <sup>c</sup>	
5-FU/SA (22)	96	15.1	177	55.4	40.3
Ingenol mebutate (18)	270	3.7	277	42.2	38.5
Imiquimod 2.5% (20) <sup>a</sup>	159	6.3	164	30.6	24.3
Imiquimod 3.75% (20) <sup>a</sup>	159	6.3	162	35.6	29.3
Imiquimod 2.5% (19) <sup>b</sup>	164	5.5	160	25.0	19.5
Imiquimod 3.75% (19) <sup>b</sup>	164	5.5	160	34.0	28.5

<sup>a</sup>Two 2-week cycles separated by a 2-week no-treatment interval. <sup>b</sup>Two 3-week cycles separated by a 3-week no-treatment interval. <sup>c</sup>8 weeks post-treatment. FU: fluorouracil; SA: salicylic acid.